The European Patent Office has given Tenax Therapeutics notice that it plans to grant a patent covering the use of levosimendan and its active metabolites to treat pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), the company said. TNX-103, an oral formulation currently in Phase 3 testing for PH-HFpEF, is among the versions […] The post Tenax sees European patent for levosimendan to treat PH-HFpEF appeared first on Pulmonary Hypertension News.
